This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CYTO Altamira Therapeutics (CYTO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisHeadlinesShort InterestTrendsBuy This Stock About Altamira Therapeutics Stock (NASDAQ:CYTO) 30 days 90 days 365 days Advanced Chart Get Altamira Therapeutics alerts:Sign Up Key Stats Today's Range$0.30▼$0.4350-Day Range$0.30▼$0.5252-Week Range$0.30▼$2.47Volume753,013 shsAverage Volume556,919 shsMarket Capitalization$1.02 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAltamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.Read More… Receive CYTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Altamira Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CYTO Stock News HeadlinesAltamira Therapeutics Ltd. (CYTOF)April 11, 2025 | finance.yahoo.comAltamira Therapeutics Amends Revenue Sharing Agreement with Altamira MedicaMarch 10, 2025 | tipranks.comReal Americans Don’t Wait on Wall Street’s Next MoveWhat's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.April 25, 2025 | Premier Gold Co (Ad)Altamira Announces Notice of Allowance from USPTO for Bentrio Nasal Spray PatentMarch 7, 2025 | markets.businessinsider.comAltamira Therapeutics Ltd (CYTOF)February 22, 2025 | investing.comAltamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting StrategiesJanuary 22, 2025 | markets.businessinsider.comAltamira Therapeutics Ltd. (CYTO) stock forecast and price targetJanuary 19, 2025 | finance.yahoo.comAltamira Therapeutics Ltd: Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNAJanuary 2, 2025 | finanznachrichten.deSee More Headlines CYTO Stock Analysis - Frequently Asked Questions When did Altamira Therapeutics' stock split? Altamira Therapeutics shares reverse split on the morning of Wednesday, December 13th 2023. The 1-20 reverse split was announced on Wednesday, December 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Altamira Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Altamira Therapeutics investors own include Plug Power (PLUG), Aridis Pharmaceuticals (ARDS), Soligenix (SNGX), Chemomab Therapeutics (CMMB), CNS Pharmaceuticals (CNSP), Cara Therapeutics (CARA) and Draganfly (DPRO). Company Calendar Today4/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CYTO CIK1601936 Webwww.aurismedical.com Phone(441) 295-5950Fax41-61-201-1351Employees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick RatioN/A Sales & Book Value Annual Sales$320,000.00 Price / Sales3.19 Cash FlowN/A Price / Cash FlowN/A Book Value$4.56 per share Price / Book0.07Miscellaneous Outstanding Shares3,400,000Free Float2,958,000Market Cap$1.02 million OptionableNot Optionable Beta1.80 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:CYTO) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altamira Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altamira Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.